Antiphospholipid Syndrome: Nephrologists’ Perspective

The spectrum of the antiphospholipid syndrome: a matter of perspective.

Should nephrologists use beta-blockers? A perspective.

Given the high prevalence of cardiovascular disease in people with chronic kidney disease (CKD) and the clear benefits of mortality reduction observed for most β−blockers in clinical trials, they are relatively underused in CKD patients [1,2]. The rationale for use of β-blockers in patients with CKD is reviewed in detail elsewhere [2,3] but is summarized in this editorial. Alterations in βand α...

Anticardiolipin syndrome: antiphospholipid syndrome.

North Am 2000;26:215–27. 14 Savill J. Recognition and phagocytosis of cells undergoing apoptosis. Br Med Bull 1997;53:491–508. 15 Elkon KB. Apoptosis in SLE – too little or too much? Review. Clin Exp Rheumatol 1994;12:553–9. 16 Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene-mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmu...

Antiphospholipid syndrome

APS can be primary or secondary. Primary antiphospholipid syndrome occurs in the absence of any other related disease. Secondary antiphospholipid syndrome is often associated with systemic lupus erythematosus and less frequently with infections, drugs and other diseases. Serologic markers are antiphospholipid antibodies, lupus anticoagulant and anticardiolipin. In rare cases, APS leads to rapid...

Antiphospholipid syndrome